Privately-held Australian biotech Cartherics has granted Shunxi Holding Group a license to develop, manufacture and commercialize its autologous CAR-T cell product, CTH-004, for multiple solid tumors including ovarian cancer in Greater China.
CTH-004 has shown promising results in animal models of ovarian cancer and will be evaluated in a clinical trial under a research and development collaboration with the Peter MacCallum Cancer Centre, announced earlier this year.
Alan Trounson, Cartherics chief executive and one of Australia’s leading embryologists with expertise in stem cell research, said: “We are pleased to see this potentially effective therapy for ovarian cancer being adopted and trialled in China, where there are many women suffering the heavy burden of ovarian cancer.
This article is accessible to registered users, to continue reading please register for free. A free trial will give you access to exclusive features, interviews, round-ups and commentary from the sharpest minds in the pharmaceutical and biotechnology space for a week. If you are already a registered user please login. If your trial has come to an end, you can subscribe here.
Login to your accountTry before you buy
7 day trial access
Become a subscriber
Or £77 per month
The Pharma Letter is an extremely useful and valuable Life Sciences service that brings together a daily update on performance people and products. It’s part of the key information for keeping me informed
Chairman, Sanofi Aventis UK
Copyright © The Pharma Letter 2024 | Headless Content Management with Blaze